 | • レポートコード：STR-DC022 • 出版社/出版日：Straits Research / 2019年11月28日 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：製薬 |
| Single User（1名様用、印刷不可） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User（5名様用） | ￥836,200 (USD5,650) | ▷ お問い合わせ |
| Enterprise Price（法人閲覧用） | ￥1,073,000 (USD7,250) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートでは、フラグメントベース創薬の世界市場について調査・分析し、調査手法、市場概要、サービスコンポーネント別（フラグメントスクリーニング、フラグメント最適化）分析、エンドユーザー別（バイオ医薬品会社、CRO）分析、地域別分析、企業概要などを含め次の構成でお届け致します。 ・イントロダクション ・調査手法 ・市場概要 ・フラグメントベース創薬の世界市場：サービスコンポーネント別（フラグメントスクリーニング、フラグメント最適化） ・フラグメントベース創薬の世界市場：エンドユーザー別（バイオ医薬品会社、CRO） ・フラグメントベース創薬の世界市場：地域別 ・企業概要 |
Global fragment-based drug discovery market was valued at USD 644.2 million in 2018 and is expected to attain USD 1541.1 million by 2025, at a CAGR of 13.3%.
Fragment-based drug discovery is the process of identifying and developing new drugs for several diseases. Fragment-based drug discovery starts with the identification of small fragment molecules which are about half size of typical drugs molecule. Later, these fragments are then optimized and interacts together to develop drug leads.
Continuous development in ‘In Silico’ methodology is driving the global fragment-based drug discovery market. The term ‘in silico’ is derived from the computer component silicium and is referred to the computational approach adopted in the drug development process. In silico methods play an important role in the fragment-based drug discovery design by supporting the identification of suitable fragments. The fragment-based approach involves the discovery of low-molecular-mass molecules. Once their interaction with the biological target molecules is clearly understood and experimentally validated, low-molecular-mass molecules signify a unique opportunity to develop potent and efficient larger compounds. In silico methods aids this whole procedure that enhance the speed and increase cost-effectiveness of the drug discovery. From the past few years, in silico methodology has been witnessing a continuous development in computational methods and aggressive launching of new computed products by companies. For instance, in June 2018, Bruker announced the scimaX MRMS resolution that would help biopharma users to perform advanced native protein and fragment-based drug discovery studies.
Increasing research activities on rare diseases is expected to support the market growth around the globe. Rare diseases are defined differently in several geographies; for instance, in the U.S., a disease that affects less than 200,000 people is considered a rare disease, whereas, in the European Union, it is defined as a disease that affects one in 2,000 people. Currently, more than 7000 rare diseases are identified across the globe, and only a fraction of them have approved treatments and therapies. Many leading pharmaceutical companies, government bodies, non-profit organizations, and policymakers are aggressively engaged in research and development activities to discover the efficient therapies to treat rare diseases.
Segmental Insights
Global fragment-based drug discovery market is segmented into service component, end user, and region.
Based on service component, the market is segmented into fragment screening and fragment optimization. Fragment screening is further segmented into biophysical techniques and non-biophysical techniques. Biophysical techniques are segregated into NMR spectroscopy, DSF assay, fluorescence polarization (FP), isothermal titration calorimetry (ITC), X-ray crystallography, surface plasmon resonance, mass spectrometry, capillary electrophoresis, and other biophysical techniques. fragment-based screening has emerged as a promising tool in the drug discovery process. Fragment-based drug design deals with the molecules having lower molecular weight ranging from100 and 300 Daltons and relatively limited functionality as compared to the larger molecules. The fragments possess affinities from the micromolar to the millimolar range, and hence the sensitive detection methods are required to identify such weak protein-ligands. Several biophysical techniques are available in the market to detect weak protein-ligand interactions such as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography. However, different biophysical techniques can be used with combinations to identify suitable hit compounds.
Computational screening tools are non-biophysical techniques and play an important role in the fragment-based drug discovery. Several computational tools are developed, accepted, and adopted by researchers, industries, and various regulatory bodies. These computational methods are useful when combined with the experimental approaches. These are fast, cost-efficient methods compatible with a wide array of biological targets. Computational methods allow the researchers to bypass the random screening of molecules across hundreds of biological targets.
Fragment optimization is one the most important steps in the fragment-based drug discovery design. Fragment-based drug discovery starts with the recognition of fragments through screening. The inadequate quality of leads emanating from screening require extensive optimization to develop drug-like properties further and to generate potential lead compounds. Fragments are screened and optimized through experimental approaches and computational methods.
Regional Insights
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.
North America dominates the global fragment-based drug discovery market. High spending on research and development and presence of large pharmaceutical companies in the region, are the vital factors driving the market. North America is further segmented into the U.S., Canada, and Mexico. The U.S. is expected to dominate the regional fragment-based drug discovery market owing to the well-developed healthcare infrastructure and presence of many CROs and companies operating in the market including Abbott Laboratories. In the U.S., FDA’s Center for Drug Evaluation and Research (CDER) plays a key role in the evaluation of new drugs before they can be sold. A team of CDER comprised of physicians, statisticians, chemists, pharmacologists, and other scientists which reviews the drugs and test it whether the drug is safe and effective for its intended use. Drug approval process in the U.S. is done through a structural framework, which includes following steps: analysis of the target condition and available treatments, assessment of benefits and risks from clinical data, and strategies for managing risks.
Europe is expected to witness significant growth in the global fragment-based drug discovery market during the forecast period 2018–2025 owing to the access to advanced technology, rising adoption of fragment-based drug discovery in academic level research, and cumulative efforts for R&D activities from several developed countries through European Union. Europe is sub-segmented into Germany, France, the U.K, Italy, Spain, and the rest of Europe. In the European region, Germany is expected to dominate the regional fragment-based drug discovery market owing to the dense network of good to an excellent university and non-university research facilities and existence of many member companies of Association of Research-Based Pharmaceutical Companies. European Union has synchronized R&D efforts of all member countries and formed the European Medicines Agency for evaluation of medicinal products. EMA is supported by thousands of experts drawn from Europe, which allows the best possible scientific expertise for the regulation of medicines. EMA has framed evaluation procedure in following steps: Pre-submission, evaluation, and post-authorization.
Key Players
Some of the major players in the fragment-based drug discovery market are, Astex Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc, Crown Bioscience, Inc., Evotec A.G, Kinetic Discovery Limited, Plexxikon Inc., Proteros Fragments GmbH, Sprint Bioscience, and Structure Based Design, Inc.
TABLE OF CONTENTS
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Market Overview
3.1 Report Segmentation & Scope
3.2 Value Chain Analysis: Fragment-Based Drug Discovery Market
3.3 Key Market Trends
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitution
3.4.4 Threat of New Entrants
3.4.5 Competitive Rivalry
3.5 Market Share Analysis
3.6 Potential Venture Avenues
3.7 Pipeline Products
4 By Service Component Overview
4.1 Introduction
4.1.1 Market Size & Forecast (Value)
4.2 Fragment Screening
4.2.1 Market Size & Forecast (Value)
4.3 Fragment Optimization
4.3.1 Market Size & Forecast (Value)
5 By End User Overview
5.1 Introduction
5.1.1 Market Size & Forecast (Value)
5.2 Biopharmaceutical Companies
5.2.1 Market Size & Forecast (Value)
5.3 CRO’s
5.3.1 Market Size & Forecast (Value)
6 Regional Overview
6.1 Introduction
6.1.1 Market Size & Forecast (Value)
6.2 America
6.2.1 North America
6.2.1.1 U.S.
6.2.1.1.1 By Service Component
6.2.1.1.2 By End User
6.2.1.2 Canada
6.2.1.2.1 By Service Component
6.2.1.2.2 By End User
6.2.1.3 Mexico
6.2.1.3.1 By Service Component
6.2.1.3.2 By End User
6.2.2 Latin America
6.2.4.1 By Service Component
6.2.4.2 By End User
6.3 Europe
6.3.1 Market Size & Forecast (Value)
6.3.2 Germany
6.3.2.1 By Service Component
6.3.2.2 By End User
6.3.3 France
6.3.3.1 By Service Component
6.3.3.2 By End User
6.3. 4 U.K
6.3.4.1 By Service Component
6.3.4.2 By End User
6.3.5 Italy
6.3.5.1 By Service Component
6.3.5.2 By End User
6.3.6 Spain
6.3.6.1 By Service Component
6.3.6.2 By End User
6.3.7 Rest of Europe
6.3.7.1 By Service Component
6.3.7.2 By End User
6.4 Asia Pacific
6.4.1 Market Size & Forecast (Value)
6.4.2 Japan
6.4.2.1 By Service Component
6.4.2.2 By End User
6.4.3 China
6.4.3.1 By Service Component
6.4.3.2 By End User
6.4.4 Australia
6.4.4.1 By Service Component
6.4.4.2 By End User
6.4.5 India
6.4.5.1 By Service Component
6.4.5.2 By End User
6.4.6 South Korea
6.4.6.1 By Service Component
6.4.6.2 By End User
6.4.7 Rest of Asia-Pacific
6.4.7.1 By Service Component
6.4.7.2 By End User
6.5 Middle East & Africa
6.5.1 Market Size & Forecast (Value)
6.5.2 Saudi Arabia
6.5.2.1 By Service Component
6.5.2.2 By End User
6.5.3 South Africa
6.5.3.1 By Service Component
6.5.3.2 By End User
6.5.4 Kuwait
6.5.4.1 By Service Component
6.5.4.2 By End User
6.5.5 Rest of Middle East & Africa
6.5.5.1 By Service Component
6.5.5.2 By End User
7 Company Profile
7.1 Astex Pharmaceuticals
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Recent Developments
7.1.4 Product Portfolio
7.2 Beactica AB
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Recent Developments
7.2.4 Product Portfolio
7.3 Charles River Laboratories International, Inc.
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Recent Developments
7.3.4 Product Portfolio
7.4 Crown Bioscience, Inc.
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Recent Developments
7.4.4 Product Portfolio
7.5 Evotec A.G
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Recent Developments
7.5.4 Product Portfolio
7.6 Kinetic Discovery Limited
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Recent Developments
7.6.4 Product Portfolio
7.7 Plexxikon Inc.
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Recent Developments
7.7.4 Product Portfolio
7.8 Proteros Fragments GmbH
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Recent Developments
7.8.4 Product Portfolio
7.9 Sprint Bioscience
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Recent Developments
7.9.4 Product Portfolio
7.10 Structure Based Design, Inc.
7.10.1 Company Overview
7.10.2 Financial Performance
7.10.3 Recent Developments
7.10.4 Product Portfolio
TABLE 1 Global Fragment-Based Drug Discovery Market Share, By Service Component, 2016–2026 ($Million)
TABLE 2 Fragment Screening Fragment-Based Drug Discovery Market Share, By Region, 2016–2026 ($ Million)
TABLE 3 Fragment Optimization Fragment-Based Drug Discovery Market Share, By Region, 2016–2026, ($ Million)
TABLE 4 Global Fragment-Based Drug Discovery Market Share, By End User, 2016–2026 ($Million)
TABLE 5 Global Fragment-Based Drug Discovery Market through Biopharmaceutical Companies, By Region, 2016–2026 ($ Million)
TABLE 6 Global Fragment-Based Drug Discovery Market Share Value, 2016–2026 ($Million)
TABLE 7 America Fragment-Based Drug Discovery Market Share Value, By Country, 2016–2026 ($Million)
TABLE 8 America Fragment-Based Drug Discovery Market Share value, By Service Component, 2016–2026 ($Million)
TABLE 9 America Fragment-Based Drug Discovery Market Share value, By End User, 2016–2026 ($Million)
TABLE 10 U.S. Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 11 U.S. Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 12 Canada Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 13 Canada Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 14 Mexico Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 15 Mexico Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 16 Latin America Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 17 Latin America Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 18 Europe Fragment-Based Drug Discovery Market Share Value, By Country, 2016–2026 ($Million)
TABLE 19 Europe Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 20 Europe Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 21 Germany Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 22 Germany Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 23 France Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 24 France Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 25 UK Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 26 UK Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 27 Italy Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 28 Italy Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 29 Spain Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 30 Spain Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 31 Rest of Europe Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 32 Rest of Europe Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 33 Asia-Pacific Fragment-Based Drug Discovery Market Share Value, By Country, 2016–2026 ($Million)
TABLE 34 Asia-Pacific Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 35 Asia-Pacific Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 36 Japan Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 37 Japan Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 38 China Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 39 China Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 40 Australia Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 41 Australia Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 42 India Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 43 India Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 44 South Korea Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 45 South Korea Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 46 Rest of Asia-pacific Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 47 Rest of Asia-pacific Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 48 LAMEA Fragment-Based Drug Discovery Market Share Value, By Country, 2016–2026 ($Million)
TABLE 49 LAMEA Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 50 LAMEA Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 51 Saudi Arabia Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 52 Saudi Arabia Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 53 South Africa Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 54 South Africa Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 55 South Africa Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 56 Brazil Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 57 Brazil Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
TABLE 58 Rest of LAMEA Fragment-Based Drug Discovery Market share, By Service Component, 2016–2026 ($Million)
TABLE 59 Rest of LAMEA Fragment-Based Drug Discovery Market share, By End User, 2016–2026 ($Million)
List of Figures
FIGURE 1 Global Fragment-Based Drug Discovery Market Overview
FIGURE 2 Value Chain Analysis
FIGURE 3 Bargaining Power of Suppliers
FIGURE 4 Bargaining Power of Buyers
FIGURE 5 Threat of Substitutes
FIGURE 6 Threat of New Entrants
FIGURE 7 Competitive Rivalry
FIGURE 8 Fragment-Based Drug Discovery Market, Market Share Analysis, 2018
FIGURE 9 Global Fragment-Based Drug Discovery Market, 2016–2026
FIGURE 10 U.S. Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 11 Canada Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 12 Mexico Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 13 Germany Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 14 France Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 15 UK Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 16 Italy Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 17 Spain Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 18 REST OF EUROPE Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 19 Japan Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 20 China Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 21 Australia Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 22 India Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 23 South Korea Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 24 Rest of Asia-pacific Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 25 Saudi Arabia Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 26 South Africa Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 27 Brazil Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 28 Rest of LAMEA Fragment-Based Drug Discovery Market Share, 2016–2026 ($Million)
FIGURE 29 Astex Pharmaceuticals: Revenue Analysis, ($million)
FIGURE 30 Astex Pharmaceuticals: Segment Revenue 2018 (%)